Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 21 January
2019
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form
40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
Issued: 21 January 2019, London UK - LSE Announcement
GSK announces succession plan to appoint new Chairman
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Sir
Philip Hampton has informed the Board of his intention to step down
as non-executive Chairman and the Board has started the process to
find a successor.
Sir Philip was appointed to the Board on 1st January
2015. He was appointed as Deputy Chairman from 1st April
2015 and as Chairman from 7th May
2015.
Sir Philip said: "It is a privilege to serve as Chairman of GSK. It
is one of the UK's great companies and under Emma Walmsley's
leadership, GSK has made very good progress with a new strategy and
new approach to R&D. Following the announcement of our deal
with Pfizer and the intended separation of the new consumer
business, I believe this is the right moment to step down and allow
a new Chair to oversee this process through to its conclusion over
the next few years and to lead the Board into this next phase for
GSK."
Vindi Banga, GSK's Senior Independent Director, said: "The Group
has a clear strategy, is delivering improved operating performance
and has a clear pathway forward, this is a good time to start the
process to find Philip's successor."
About GSK
GSK is a science-led global healthcare company with a special
purpose: to help people do more, feel better, live longer. For
further information please visit www.gsk.com.
|
GSK enquiries:
|
|
|
|
|
UK Media enquiries:
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Analyst/Investor enquiries:
|
Sarah Elton-Farr
|
+44 (0) 208 047 5194
|
(London)
|
|
|
Danielle Smith
|
+44 (0) 20 8047 7562
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mel Foster-Hawes
|
+44 (0) 20 8047 0674
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Cautionary statements regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described under Item 3.D
Principal risks and uncertainties in the company's Annual Report on
Form 20-F for 2017.
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: January
21, 2019
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|